Rifapentine, Terbinafine Hcl,Imiquimod, Butenafine HCL passed GMP inspection

2019-10-18

Download

Rifapentine, Terbinafine Hcl,Imiquimod,
Butenafine HCL passed GMP inspection
In June and September of 2017, 4 API products of Chongqing Huapont Pharma transferred
from Sichuan Medshing Pharmaceutical have passed the current inspection of CFDA, which
include: Rifapentine, Terbinafine Hcl, Imiquimod, Butenafine HCL. GMP of the 4
products will be receive in early 2018. Since 2017,8 API products of Sichuan Medshine: Rifapentine, Rifabutine, Terbinafine Hcl, Imiquimod, Butenafine HCL, Benzoyl peroxide, Valaciclovir, Adapalene are gradually
transferred to Chongqing Huapont Huapont Shengchem. GMP of the 8 API products will be
received in the first half year of 2018. Please do not hesitate to contact us:
Email: mike.wang@huapont.cn
Tel: 0086-23-67886928 | Fax: 0086-23-67886927
www.huapont.cn
About Sichuan Medshine
Sichuan Medshing is a Pharmaceutical company located in Wenjiang, Sichuan province which is strong in the area of dermatology and anti-TB. Chongqing Huapoont merged Sichuan Medshing Pharmaceutical in June of 2013 with ¥100.5 million which greatly enriched their production line.